Nurix Therapeutics, Inc.
NRIX
$12.46
$0.201.59%
NASDAQ
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -82.08% | 138.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -82.08% | 138.75% | |||
| Cost of Revenue | 10.27% | 12.11% | |||
| Gross Profit | -129.81% | 33.53% | |||
| SG&A Expenses | -7.86% | 22.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.47% | 13.60% | |||
| Operating Income | -89.12% | 23.13% | |||
| Income Before Tax | -102.37% | 24.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -98.83% | 22.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -98.83% | 22.87% | |||
| EBIT | -89.12% | 23.13% | |||
| EBITDA | -93.92% | 23.85% | |||
| EPS Basic | -98.17% | 23.16% | |||
| Normalized Basic EPS | -101.70% | 24.51% | |||
| EPS Diluted | -98.17% | 23.16% | |||
| Normalized Diluted EPS | -101.70% | 24.51% | |||
| Average Basic Shares Outstanding | 0.33% | 0.38% | |||
| Average Diluted Shares Outstanding | 0.33% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||